The FDA approval is based on the results of an Octapharma-sponsored clinical trial to evaluate the safety and efficacy of Octagam 10% in 66 patients ages 17–88 years old with chronic ITP. In a clinical study of adults with chronic ITP, Octagam 10% delivered rapid and sustained results without compromising tolerability.
Octagam 10% is a solvent/detergent treated, sterile preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma.
Octagam 10% is available in 2g, 5g, 10g, and 20g single-use bottles.
For more information call (888) 429-4535 or visit Octapharma.com.